A phase II randomized study of DP(Docetaxel+Cisplatin),DJ(Docetaxel+Carboplatin),and TJ(Paclitaxel+Carboplatin) in patients with advanced and recurrent endometrial carcinoma

Phase 2

• Conditions: advanced or recurrent endometrial carcinoma

• Registration Number: JPRN-C000000170
• Lead Sponsor: Japanese Gynecologic Oncology Group

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2005-09-15
• Study Completion: 2006-07-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: Female
• Target Recruitment: 90

Inclusion Criteria

Not provided

Exclusion Criteria

-Patients with sarcomatous element -Active infections -Serious complications (heart disease, interstitial lung disease, uncontrolled hypertension, diabetes mellitus and tendency to bleeding) -Massive pleural effusion or ascites -Neuropathy grade 2 or more; edema grade 2 or more (NCI-CTC) -Active concomitant malignancy -Hypersensitivity to Polysorbate 80 or Cremophor EL -Patients judged inappropriate for this study by the physicians

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Tumor Response

Secondary Outcome Measures

Name	Time	Method
Toxicity, Feasibility, Progression free survival